Page 225 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

204 PART 3 Therapeutic Modalities for the Cancer Patient

219. Crespi MD, Ivanier SE, Genovese J, et al.: Mitoxantrone affects 240. Kufe DW, Major PP, Egan EM, et al.: Correlation of cytotoxicity
topoisomerase activities in human breast cancer cells, Biochem Bio- with incorporation of ara-C into DNA, J Biol Chem 255, 1980.
phys Res Commun 136:521–528, 1986. 8997–8900.
VetBooks.ir 220. Patterson LH, Gandecha BM, Brown JR: 1,4-bis(2-[(2-hydroxyethyl) 241. Major PP, Egan EM, Herrick DJ, et al.: Effect of ara-C incorpora-
tion on deoxyribonucleic acid synthesis in cells, Biochem Pharmacol
amino]ethylamino)-9,10-anthracenedione, an anthraquinone antitu-
mour agent that does not cause lipid peroxidation in vivo; compari-
31:2937–2940, 1982.
son with daunorubicin, Biochem Biophys Res Commun 110:399–405, 242. Mikita T, Beardsley GP: Functional consequences of the arabino-
1983. sylcytosine structural lesion in DNA, Biochemistry 27:4698–4705,
221. Nguyen B, Gutierrez PL: Mechanism(s) for the metabolism of 1988.
mitoxantrone: electron spin resonance and electrochemical studies, 243. Bianchi Scarra GL, Romani M, Coviello DA, et al.: Termi-
Chem Biol Interact 74:139–162, 1990. nal erythroid differentiation in the k-562 cell line by 1-beta-
222. Alberts DS, Peng YM, Leigh S, et al.: Disposition of mitoxantrone d- arabinofuranosylcytosine: accompaniment by c-myc messenger
in cancer patients, Cancer Res 45:1879–1884, 1985. RNA decrease, Cancer Res 46:6327–6332, 1986.
223. Lu K, Savaraj N, Loo TL: Pharmacological disposition of 244. Plagemann PG, Marz R, Wohlhueter RM: Transport and metabo-
1,4-dihydroxy-5-8-bis[[2 [(2-hydroxyethyl)amino]ethyl]amino]- lism of deoxycytidine and 1-beta-d-arabinofuranosylcytosine into
9,10- anthracenedione dihydrochloride in the dog, Cancer Che- cultured novikoff rat hepatoma cells, relationship to phosphoryla-
mother Pharmacol 13:63–66, 1984. tion, and regulation of triphosphate synthesis, Cancer Res 38:978–
224. Chiccarelli FS, Morrison JA, Cosulich DB, et al.: Identification of 989, 1978.
human urinary mitoxantrone metabolites, Cancer Res 46:4858– 245. Garcia-Carbonero R, Ryan DP, Chabner BA: Cytidine analogs.
4861, 1986. In Chabner BA, Longo DL, editors: Cancer chemotherapy & bio-
225. Henry CJ, McCaw DL, Turnquist SE, et al.: Clinical evaluation of therapy: principles and practice, Philadelphia, 2001, Lippincott Wil-
mitoxantrone and piroxicam in a canine model of human invasive liams & Wilkins, pp 265–294.
urinary bladder carcinoma, Clin Cancer Res 9:906–911, 2003. 246. Scott-Moncrieff JC, Chan TC, Samuels ML, et al.: Plasma and
226. Turek MM, Forrest LJ, Adams WM, et al.: Postoperative radio- cerebrospinal fluid pharmacokinetics of cytosine arabinoside in
therapy and mitoxantrone for anal sac adenocarcinoma in the dog: dogs, Cancer Chemother Pharmacol 29:13–18, 1991.
15 cases (1991–2001), Vet Comp Oncol 1:94–104, 2003. 247. Ruslander D, Moore AS, Gliatto JM, et al.: Cytosine arabinoside as
227. Wang SL, Lee JJ, Liao AT: Comparison of efficacy and toxicity of a single agent for the induction of remission in canine lymphoma,
doxorubicin and mitoxantrone in combination chemotherapy for J Vet Intern Med 8:299–301, 1994.
canine lymphoma, Can Vet J 57:271–276, 2016. 248. Alvarez FJ, Kisseberth WC, Gallant SL, et al.: Dexamethasone,
228. Lucroy MD, Phillips BS, Kraegel SA, et al.: Evaluation of single- melphalan, actinomycin D, cytosine arabinoside (DMAC) proto-
agent mitoxantrone as chemotherapy for relapsing canine lym- col for dogs with relapsed lymphoma, J Vet Intern Med 20:1178–
phoma, J Vet Intern Med 12:325–329, 1998. 1183, 2006.
229. Takusagawa F, Dabrow M, Neidle S, et al.: The structure of a 249. Marconato L, Bonfanti U, Stefanello D, et al.: Cytosine arabino-
pseudo intercalated complex between actinomycin and the DNA side in addition to VCAA-based protocols for the treatment of
binding sequence d(GpC), Nature 296:466–469, 1982. canine lymphoma with bone marrow involvement: does it make
230. Takusagawa F, Goldstein BM, Youngster S, et al.: Crystallization the difference? Vet Comp Oncol 6:80–89, 2008.
and preliminary x-ray study of a complex between d(ATGCAT) 250. Menaut P, Landart J, Behr S, et al.: Treatment of 11 dogs with
and actinomycin D, J Biol Chem 259:4714–4715, 1984. meningoencephalomyelitis of unknown origin with a combination
231. Brown SC, Mullis K, Levenson C, et al.: Aqueous solution struc- of prednisolone and cytosine arabinoside, Vet Rec 162:241–245,
ture of an intercalated actinomycin D-dATGCAT complex by 2008.
two-dimensional and one-dimensional proton nmr, Biochemistry 251. Smith PM, Stalin CE, Shaw D, et al.: Comparison of two regimens
23:403–408, 1984. for the treatment of meningoencephalomyelitis of unknown etiol-
232. Wadkins RM, Jovin TM: Actinomycin D and 7-aminoactinomycin ogy, J Vet Intern Med 23:520–526, 2009.
D binding to single-stranded DNA, Biochemistry 30:9469–9478, 252. Allegra CJ, Fine RL, Drake JC, et al.: The effect of methotrexate
1991. on intracellular folate pools in human mcf-7 breast cancer cells:
233. Goldberg IH, Rabinowitz M, Reich E: Basis of actinomycin action. evidence for direct inhibition of purine synthesis, J Biol Chem
I. DNA binding and inhibition of RNA-polymerase synthetic reac- 261:6478–6485, 1986.
tions by actinomycin, Proc Natl Acad Sci USA 48:2094–2101, 1962. 253. Allegra CJ, Chabner BA, Drake JC, et al.: Enhanced inhibition of
234. Reich E, Franklin RM, Shatkin AJ, et al.: Action of actinomycin D thymidylate synthase by methotrexate polyglutamates, J Biol Chem
on animal cells and viruses, Proc Natl Acad Sci USA 48:1238–1245, 260:9720–9726, 1985.
1962. 254. Fabre I, Fabre G, Goldman ID: Polyglutamylation, an important
235. Kessel D, Wodinsky I: Uptake in vivo and in vitro of actinomycin element in methotrexate cytotoxicity and selectivity in tumor
D by mouse leukemias as factors in survival, Biochem Pharmacol versus murine granulocytic progenitor cells in vitro, Cancer Res
17:161–164, 1968. 44:3190–3195, 1984.
236. Inaba M, Johnson RK: Decreased retention of actinomycin D as 255. Wan SH, Huffman DH, Azarnoff DL, et al.: Effect of route of
the basis for cross-resistance in anthracycline-resistant sublines of administration and effusions on methotrexate pharmacokinetics,
p388 leukemia, Cancer Res 37:4629–4634, 1977. Cancer Res 34:3487–3491, 1974.
237. Diddens H, Gekeler V, Neumann M, et al.: Characterization of 256. Bischoff KB, Dedrick RL, Zaharko DS, et al.: Methotrexate phar-
actinomycin-D-resistant cho cell lines exhibiting a multidrug- macokinetics, J Pharm Sci 60:1128–1133, 1971.
resistance phenotype and amplified DNA sequences, Int J Cancer 257. Mackey JR, Mani RS, Selner M, et al.: Functional nucleoside trans-
40:635–642, 1987. porters are required for gemcitabine influx and manifestation of
238. Galbraith WM, Mellett LB: Tissue disposition of 3h-actinomycin toxicity in cancer cell lines, Cancer Res 58:4349–4357, 1998.
D (NSC-3053) in the rat, monkey, and dog, Cancer Chemother Rep 258. Gandhi V, Plunkett W: Modulatory activity of 2′,2′-difluorode-
59:1601–1609, 1975. oxycytidine on the phosphorylation and cytotoxicity of arabinosyl
239. Furth JJ, Cohen SS: Inhibition of mammalian DNA polymerase by nucleosides, Cancer Res 50:3675–3680, 1990.
the 5′-triphosphate of 1-beta-d-arabinofuranosylcytosine and the 259. Gandhi V, Legha J, Chen F, et al.: Excision of 2′,2′-difluorodeoxy-
5′-triphosphate of 9-beta-d-arabinofuranoxyladenine, Cancer Res cytidine (gemcitabine) monophosphate residues from DNA, Can-
28:2061–2067, 1968. cer Res 56:4453–4459, 1996.